MarketCap
Facebook
X
Telegram
electroCore Revenue | ECOR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue electroCore
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32 M | 25.2 M | 16 M | 8.59 M | 5.45 M | 3.5 K | 2.39 M | 993 K | 811 K | 254 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32 M | 3.5 K | 9.17 M |
Quarterly Revenue electroCore
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.45 M | 9.58 M | 8.69 M | 7.38 M | 6.72 M | - | 6.55 M | 6.14 M | 5.44 M | - | 4.51 M | 3.55 M | 2.78 M | - | 1.98 M | 2.16 M | 1.9 M | - | 1.49 M | 1.27 M | 1.2 M | - | 1.08 M | 753 K | 734 K | - | 683 K | 623 K | 410 K | 368 K | 151 K | 393 K | 81.2 K | 234 K | 283 K | 177 K | 117 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.58 M | 81.2 K | 2.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
STAAR Surgical Company
STAA
|
239 M | $ 24.16 | 2.94 % | $ 1.2 B |  USA |
 |
Stereotaxis
STXS
|
32.4 M | $ 1.3 | 0.36 % | $ 118 M | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 1.5 | 4.17 % | $ 68.7 M |  Israel |
 |
Retractable Technologies
RVP
|
38.3 M | $ 0.7 | 1.29 % | $ 21 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 10.99 | 0.48 % | $ 2.19 B | USA |
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | USA |
 |
Utah Medical Products
UTMD
|
9.04 M | $ 69.16 | 0.55 % | $ 224 M | USA |
 |
Teleflex Incorporated
TFX
|
569 M | $ 137.0 | 0.38 % | $ 6.11 B | USA |
 |
West Pharmaceutical Services
WST
|
3.07 B | $ 337.75 | 0.03 % | $ 24.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
Alcon
ALC
|
10.4 B | $ 69.12 | 0.3 % | $ 34.1 B |  Schweiz |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
AngioDynamics
ANGO
|
320 M | $ 15.22 | 0.13 % | $ 632 M | USA |
 |
AtriCure
ATRC
|
535 M | $ 53.73 | 4.29 % | $ 2.57 B | USA |
 |
Baxter International
BAX
|
11.2 B | $ 24.86 | 1.02 % | $ 12.8 B | USA |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 179.1 | 0.05 % | $ 51.5 B | USA |
 |
BioLife Solutions
BLFS
|
96.2 M | $ 35.38 | 0.37 % | $ 1.69 B | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
The Cooper Companies
COO
|
4.09 B | $ 67.69 | 1.31 % | $ 13.5 B | USA |
 |
Glaukos Corporation
GKOS
|
507 M | $ 185.04 | 4.27 % | $ 10.6 B | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
Haemonetics Corporation
HAE
|
1.33 B | $ 102.84 | 0.24 % | $ 4.85 B | USA |
 |
Harvard Bioscience
HBIO
|
86.6 M | $ 7.95 | 1.62 % | $ 353 M | USA |
 |
ICU Medical
ICUI
|
2.23 B | $ 160.89 | 0.78 % | $ 3.96 B | USA |
 |
InfuSystem Holdings
INFU
|
143 M | $ 11.89 | 0.74 % | $ 246 M | USA |
 |
iRhythm Technologies
IRTC
|
747 M | $ 122.24 | 0.77 % | $ 3.91 B | USA |
 |
Intuitive Surgical
ISRG
|
10.1 B | $ 350.16 | 0.28 % | $ 125 B | USA |
 |
Repro Med Systems
KRMD
|
41.1 M | $ 3.17 | 0.93 % | $ 146 M | USA |
 |
LeMaitre Vascular
LMAT
|
250 M | $ 79.59 | 0.22 % | $ 1.8 B | USA |
 |
Milestone Scientific
MLSS
|
8.97 M | $ 0.44 | 0.52 % | $ 36.1 M | USA |
 |
Merit Medical Systems
MMSI
|
1.52 B | $ 87.38 | 1.16 % | $ 5.17 B | USA |
 |
Nephros
NEPH
|
18.8 M | $ 4.36 | 7.39 % | $ 46.3 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.72 B | $ 26.81 | 0.73 % | $ 4.5 B | USA |
 |
OraSure Technologies
OSUR
|
115 M | $ 3.39 | 2.27 % | $ 249 M | USA |
 |
Pro-Dex
PDEX
|
77.5 M | $ 66.41 | 18.88 % | $ 214 B | USA |
 |
Pulse Biosciences
PLSE
|
350 K | $ 48.79 | 3.85 % | $ 3.29 B | USA |
 |
ResMed
RMD
|
5.65 B | $ 221.05 | 0.04 % | $ 32.2 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
71.6 M | - | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
1.43 M | - | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
2.09 B | - | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
125 K | - | - | $ 31.1 M | USA |
 |
Repligen Corporation
RGEN
|
738 M | $ 168.53 | 0.55 % | $ 9.48 M | USA |
 |
STERIS plc
STE
|
5.94 B | $ 218.44 | 0.31 % | $ 21.5 B | USA |